The Disruptive Voice
69. Bioengineering at Scale, A Conversation with Anna Marie Wagner of Ginkgo Bioworks
Feb 26, 2021
Anna Marie Wagner from Ginkgo Bioworks discusses the transformative potential of bioengineering and the barriers to biotech development, showcasing Ginkgo's platform solution for biological innovation. Topics include fearlessness in entrepreneurship, revenue models in bioengineering, disrupting the synthetic biology industry, navigating pandemic challenges, and transitioning to startup culture.
44:16
Episode guests
AI Summary
AI Chapters
Episode notes
Podcast summary created with Snipd AI
Quick takeaways
- Ginko Bioworks utilizes synthetic biology to revolutionize industries through DNA programming.
- AnnaMarie Wagner highlights the importance of embracing uncertainty and challenging conventional norms in high-growth companies.
Deep dives
AnnaMarie Wagner's Career Path to Ginko
AnnaMarie Wagner's journey to Ginko BioWorks traces back to her undergrad days studying molecular and cellular biology, conducting bioengineering competitions, and eventually transitioning to economics and finance. Despite a successful career in investing at Bain Capital's private equity team, she realized her passion lay in building something impactful. Serendipitously introduced to Ginko's founders, who were creating a synthetic biology platform, AnnaMarie found a mission aligned with her academic background and aspirations, leading to her current role driving corporate development at Ginko.
Remember Everything You Learn from Podcasts
Save insights instantly, chat with episodes, and build lasting knowledge - all powered by AI.
